Clinical Trial Update: Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating anti-PD-1 therapy plus thymalfasin and the SOX regimen (S-1 + oxaliplatin) in clinical stage III gastric or gastroesophagea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Anti-PD-1 (PD-1 inhibitor) (PD-1 inhibitor)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Thymalfasin (thymosin alpha-1) (thymosin alpha-1)

Snippet

Sponsor: Zekuan Xu | Conditions: Gastric Cancer, Esophagogastric Junction Adenocarcinoma | Phase 2 | Status: RECRUITING